Hospital
Uh Regional Hospitals
Uh Regional Hospitals was paid $23.17M by Medicaid between Jan 2018 and Dec 2024, across 261 billing codes. Its largest line is 99283, emergency room visit (moderate) — 26% of everything it billed.
33Billing provider infoUH REGIONAL HOSPITALS
CHARDON, OH 44024
CHARDON, OH 44024
33aNPI1669562864assigned 10/16/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$23.17M
24GClaims588,882
24DCodes billed261
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Ohio
Rank by total paid#50 of 101
Median peer was paid$22.32M
This provider vs. median1.0×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official SCHILLERO, ANTHONY controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 83,127 | $2.97M | |
| 2019 | 95,304 | $4.08M | |
| 2020 | 70,846 | $3.58M | |
| 2021 | 83,393 | $3.45M | |
| 2022 | 61,229 | $2.44M | |
| 2023 | 115,930 | $4.06M | |
| 2024incomplete | 79,053 | $2.58M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 26% | 49,975 | 47,969 | $5.91M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 14% | 24,779 | 23,100 | $3.28M |
| 96361 | Intravenous infusion, hydration; each additional hour | 10% | 8,687 | 7,625 | $2.33M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 10.0% | 19,650 | 17,488 | $2.31M |
| D2930 | Prefabricated stainless steel crown - primary tooth | 3.5% | 1,222 | 285 | $813K |
| 70450 | Computed tomography, head or brain; without contrast material | 3.0% | 3,378 | 2,933 | $706K |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 2.8% | 7,267 | 6,478 | $645K |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 2.4% | 5,520 | 4,923 | $546K |
| 41899 | Unlisted procedure, dentoalveolar structures | 2.1% | 721 | 699 | $476K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 1.9% | 6,394 | 2,568 | $440K |
| D3220 | Therapeutic pulpotomy (excluding final restoration) - removal of pulp coronal to the dentinocemental junction | 1.8% | 725 | 179 | $414K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 1.8% | 1,877 | 1,541 | $408K |
249 more codes
| 99215 | Doctor's office visit, returning patient (complex) | 1.6% | 3,461 | $372K |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | 1.3% | 2,787 | $290K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | 1.2% | 1,071 | $285K |
| 80053 | Comprehensive metabolic panel | 1.2% | 35,848 | $284K |
| G0378 | Hospital observation service, per hour | 1.1% | 5,155 | $252K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 477 | $203K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 1,545 | $167K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 1,324 | $164K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 769 | $151K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 526 | $123K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 537 | $121K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 1,205 | $117K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 552 | $116K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 9,167 | $103K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 487 | $81K |
| 84484 | <1% | 17,306 | $77K | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 647 | $76K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 4,405 | $60K |
| 11045 | <1% | 438 | $59K | |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 3,422 | $57K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 3,521 | $56K |
| D7140 | Extraction, erupted tooth or exposed root | <1% | 109 | $56K |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 1,100 | $55K |
| 97161 | <1% | 1,088 | $51K | |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 358 | $51K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 19,808 | $49K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 522 | $48K |
| 85027 | <1% | 8,899 | $45K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 3,553 | $43K |
| 71045 | Radiologic examination, chest; single view | <1% | 12,008 | $41K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 41,314 | $38K |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 3,324 | $35K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 1,227 | $35K |
| D2392 | Resin-based composite - two surfaces, posterior, primary or permanent | <1% | 48 | $34K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 1,694 | $34K |
| 94060 | <1% | 351 | $33K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 1,867 | $33K |
| 80061 | Lipid panel | <1% | 2,357 | $33K |
| 73564 | <1% | 715 | $31K | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 691 | $30K |
| 86780 | <1% | 961 | $30K | |
| 71250 | <1% | 359 | $29K | |
| 73030 | <1% | 720 | $29K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 17,189 | $29K |
| 83605 | <1% | 6,515 | $25K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 6,015 | $23K |
| 76642 | <1% | 248 | $23K | |
| 97165 | <1% | 426 | $23K | |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | <1% | 696 | $22K |
| 74018 | <1% | 473 | $22K | |
| 73630 | <1% | 678 | $22K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 954 | $21K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 204 | $21K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 17,037 | $19K |
| 73610 | <1% | 567 | $19K | |
| 73130 | <1% | 547 | $17K | |
| 73110 | <1% | 433 | $17K | |
| D2150 | Silver amalgam - two surfaces, primary or permanent | <1% | 22 | $16K |
| 73502 | <1% | 392 | $16K | |
| 97162 | <1% | 350 | $15K | |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 42 | $15K |
| 86850 | <1% | 772 | $14K | |
| 94729 | <1% | 391 | $14K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 1,153 | $14K |
| 87631 | <1% | 131 | $13K | |
| 82805 | <1% | 603 | $13K | |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | <1% | 26 | $12K |
| 76830 | Ultrasound, transvaginal | <1% | 368 | $12K |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 498 | $12K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 973 | $12K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 761 | $11K |
| 72110 | <1% | 171 | $10K | |
| 73560 | <1% | 194 | $9K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 11,416 | $9K |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 17 | $9K |
| D2391 | Resin-based composite - one surface, posterior, primary or permanent | <1% | 14 | $9K |
| 94727 | <1% | 206 | $8K | |
| 73562 | <1% | 211 | $8K | |
| 86900 | <1% | 795 | $8K | |
| 93246 | <1% | 148 | $8K | |
| 76536 | <1% | 72 | $8K | |
| 93242 | <1% | 97 | $7K | |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 693 | $7K |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 56 | $7K |
| 51798 | <1% | 576 | $7K | |
| 59025 | Fetal non-stress test | <1% | 38 | $7K |
| 83880 | <1% | 2,144 | $7K | |
| 93971 | <1% | 121 | $7K | |
| 81001 | <1% | 16,075 | $7K | |
| 83735 | <1% | 5,262 | $6K | |
| 97116 | <1% | 329 | $6K | |
| 80069 | <1% | 666 | $6K | |
| 81003 | <1% | 14,613 | $6K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 4,216 | $6K |
| 93017 | <1% | 74 | $6K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 7,672 | $5K |
| 76982 | <1% | 121 | $5K | |
| 82947 | <1% | 3,031 | $5K | |
| 87340 | <1% | 342 | $5K | |
| 85610 | <1% | 8,256 | $5K | |
| 81025 | <1% | 12,639 | $5K | |
| 76770 | <1% | 27 | $4K | |
| 73140 | <1% | 60 | $4K | |
| 96367 | <1% | 70 | $4K | |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 60 | $4K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 1,262 | $4K |
| 96376 | <1% | 1,911 | $4K | |
| J3490 | Unclassified drugs | <1% | 1,711 | $4K |
| 82728 | <1% | 216 | $4K | |
| 84439 | <1% | 161 | $3K | |
| C8929 | Transthoracic echocardiography with contrast, or without contrast followed by with contrast, real-time with image documentation (2d), includes m-mode recording, when performed, complete, with spectral doppler echocardiography, and with color flow doppler echocardiography | <1% | 15 | $3K |
| 80076 | <1% | 521 | $3K | |
| 82607 | <1% | 131 | $3K | |
| 94664 | <1% | 119 | $3K | |
| 80320 | <1% | 194 | $3K | |
| 83690 | <1% | 6,537 | $3K | |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 16 | $3K |
| 86140 | <1% | 407 | $3K | |
| 99152 | <1% | 257 | $3K | |
| 86901 | <1% | 795 | $3K | |
| 87040 | <1% | 721 | $2K | |
| 72050 | <1% | 32 | $2K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 1,808 | $2K |
| 83540 | <1% | 202 | $2K | |
| 87081 | <1% | 1,386 | $2K | |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | <1% | 42 | $2K |
| 83550 | <1% | 194 | $2K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 1,875 | $2K |
| 84702 | <1% | 1,245 | $2K | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 10,903 | $2K |
| 73090 | <1% | 54 | $2K | |
| 82077 | <1% | 944 | $1K | |
| 84481 | <1% | 114 | $1K | |
| 85379 | <1% | 865 | $1K | |
| 93922 | <1% | 12 | $1K | |
| 90715 | <1% | 104 | $1K | |
| 73080 | <1% | 26 | $1K | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 1,663 | $1K |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 224 | $1K |
| 72131 | <1% | 42 | $971.45 | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 2,417 | $866.07 |
| 80143 | <1% | 658 | $856.71 | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 1,062 | $828.37 |
| 72170 | <1% | 112 | $771.29 | |
| 82550 | <1% | 566 | $691.68 | |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 950 | $688.12 |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 1,548 | $675.33 |
| 87077 | <1% | 247 | $645.94 | |
| 99406 | <1% | 32 | $639.85 | |
| 86592 | <1% | 55 | $599.10 | |
| 70486 | <1% | 13 | $598.04 | |
| 80178 | <1% | 32 | $593.74 | |
| 85730 | <1% | 895 | $592.79 | |
| 72100 | <1% | 14 | $589.89 | |
| 73590 | <1% | 30 | $532.78 | |
| 83021 | <1% | 27 | $513.80 | |
| 82330 | <1% | 478 | $507.90 | |
| 87210 | <1% | 666 | $487.65 | |
| 84100 | <1% | 507 | $461.40 | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 152 | $449.24 |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 8,733 | $444.08 |
| 80179 | <1% | 643 | $418.16 | |
| 85018 | <1% | 559 | $415.53 | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 3,304 | $415.01 |
| 87186 | <1% | 367 | $410.75 | |
| 94761 | <1% | 1,827 | $368.55 | |
| 85652 | <1% | 254 | $359.90 | |
| 00731 | <1% | 418 | $354.20 | |
| 84132 | <1% | 525 | $351.45 | |
| 82962 | <1% | 336 | $345.51 | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 125 | $337.58 |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 4,505 | $335.14 |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | <1% | 12 | $332.94 |
| J1815 | Injection, insulin, per 5 units | <1% | 53 | $332.75 |
| 82948 | <1% | 774 | $317.28 | |
| A9270 | Non-covered item or service | <1% | 10,822 | $315.52 |
| 80346 | <1% | 13 | $304.67 | |
| 86762 | <1% | 28 | $287.67 | |
| 87075 | <1% | 434 | $271.11 | |
| 82435 | <1% | 445 | $255.37 | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 8,929 | $231.94 |
| 83615 | <1% | 68 | $230.95 | |
| 73552 | <1% | 20 | $228.21 | |
| J8499 | Prescription drug, oral, non chemotherapeutic, nos | <1% | 789 | $225.96 |
| 84295 | <1% | 458 | $182.52 | |
| C9113 | Injection, pantoprazole sodium, per vial | <1% | 117 | $176.00 |
| 87634 | <1% | 135 | $166.80 | |
| M0247 | Intravenous infusion, sotrovimab, includes infusion and post administration monitoring | <1% | 15 | $161.36 |
| 80361 | <1% | 13 | $152.33 | |
| 82570 | <1% | 19 | $147.91 | |
| G0404 | Electrocardiogram, routine ecg with 12 leads; tracing only, without interpretation and report, performed as a screening for the initial preventive physical examination | <1% | 30 | $137.55 |
| J2543 | Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams) | <1% | 51 | $112.01 |
| J2704 | Injection, propofol, 10 mg | <1% | 2,737 | $111.81 |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 605 | $101.78 |
| 84703 | <1% | 110 | $89.76 | |
| 88304 | <1% | 22 | $78.97 | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 3,607 | $76.01 |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 749 | $73.59 |
| 87070 | <1% | 17 | $68.91 | |
| J0689 | Injection, cefazolin sodium (baxter), not therapeutically equivalent to j0690, 500 mg | <1% | 37 | $64.48 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 533 | $59.14 |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 445 | $57.45 |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 84 | $57.10 |
| J7999 | Compounded drug, not otherwise classified | <1% | 95 | $53.14 |
| 74019 | <1% | 16 | $52.42 | |
| 87205 | <1% | 17 | $51.25 | |
| J2360 | Injection, orphenadrine citrate, up to 60 mg | <1% | 176 | $48.84 |
| 77066 | Tomosynthesis, mammo | <1% | 17 | $48.75 |
| J3370 | Injection, vancomycin hcl, 500 mg | <1% | 22 | $45.55 |
| A4217 | Sterile water/saline, 500 ml | <1% | 310 | $43.90 |
| J3480 | Injection, potassium chloride, per 2 meq | <1% | 37 | $38.20 |
| 84550 | <1% | 37 | $36.94 | |
| 81002 | <1% | 704 | $34.59 | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 443 | $32.55 |
| 82248 | <1% | 50 | $31.98 | |
| Q9957 | Injection, perflutren lipid microspheres, per ml | <1% | 222 | $29.70 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 3,108 | $28.26 |
| J7060 | 5% dextrose/water (500 ml = 1 unit) | <1% | 85 | $22.40 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 1,482 | $21.80 |
| 82150 | <1% | 69 | $16.07 | |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 252 | $13.52 |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | <1% | 68 | $12.12 |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 342 | $8.17 |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 59 | $5.24 |
| J2060 | Injection, lorazepam, 2 mg | <1% | 29 | $3.95 |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | <1% | 144 | $3.66 |
| J1171 | Injection, hydromorphone, 0.1 mg | <1% | 96 | $2.58 |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 54 | $1.32 |
| J7620 | Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme | <1% | 137 | $1.03 |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 154 | $0.24 |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | <1% | 248 | $0.11 |
| 00170 | Anesthesia for intraoral procedures, including biopsy | 0% | 871 | $0.00 |
| A9575 | Injection, gadoterate meglumine, 0.1 ml | 0% | 461 | $0.00 |
| C1887 | Catheter, guiding (may include infusion/perfusion capability) | 0% | 37 | $0.00 |
| 0753T | 0% | 22 | $0.00 | |
| Q9966 | Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml | 0% | 48 | $0.00 |
| A9502 | Technetium tc-99m tetrofosmin, diagnostic, per study dose | 0% | 17 | $0.00 |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | 0% | 21 | $0.00 |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | 0% | 55 | $0.00 |
| J1596 | Injection, glycopyrrolate, 0.1 mg | 0% | 12 | $0.00 |
| J2004 | Injection, lidocaine hcl with epinephrine, 1 mg | 0% | 12 | $0.00 |
| 00840 | 0% | 20 | $0.00 | |
| D0272 | Bitewings - two radiographic images | 0% | 120 | $0.00 |
| 94760 | 0% | 771 | $0.00 | |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | 0% | 69 | $0.00 |
| 76377 | 0% | 27 | $0.00 | |
| 87800 | 0% | 17 | $0.00 | |
| 82553 | 0% | 13 | $0.00 | |
| Q0247 | Injection, sotrovimab, 500 mg | 0% | 15 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialSCHILLERO, ANTHONY (DIRECTOR, FP&A)
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.